Methamphetamine dependence disorder. Opioid dependence
Conditions
Interventions
Intervention 1: Intervention group: Direct current will be delivered using a StarStimtCS system and transferred by a pair of circular stimulation electrodes with 1 cm radius. They have rear-fill apert
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
Male
Age
18 Years to 61 Years
Inclusion criteria
Inclusion criteria: Male gender Age =18 and <61 years old Farsi speaking Diagnosed with Methamphetamine Use Disorder (last 12 months) based on Structured Clinical Interview for DSM-5 (SCID-5) Abstinent from any drugs except cigarettes for at least one week based on medical records or self-report, confirmed by urine analysis Positive response to Methamphetamine cue-reactivity screening (MCS) Willing and capable of interacting with the informed consent process8. The ability to understand, read and answer the tests
Exclusion criteria
Exclusion criteria: Unwillingness or inability to complete any of the major aspects of the study protocol, including drug cue rating, or behavioral assessment. Abstinence from methamphetamine for more than 6 months based on self-report Any major clinical psychiatric disorder, assessed by Structured Clinical Interview for DSM-5 (SCID-5) Active suicidal ideation with intent or plan determined by self-report or assessment by PI or study staff during the initial screening or any other phase of the study Positive drug test for amphetamines, opioids, cannabis confirmed by urine tests Any active skin disorder that affects skin integrity of the scalp Having any condition that would preclude undergoing a tDCS stimulation based on the tDCS safety checklist Unstable medical disorder reported in subject’s medical history or by a clinician assessment History of major head trauma, seizure, brain surgery, intracranial metal implantation Non-correctable vision or hearing problems.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Amplitude of event-related potentials with middle latency (P3). Timepoint: Immediately before and after intervention. Method of measurement: Event-related potentials will be recorded using a bio-signal amplifier with CE & FDA approval (g.HIamp, g.tec company ) from 62 scalp sites.;Amplitude of event-related potentials with late latency (LPP). Timepoint: Immediately before and after intervention. Method of measurement: Event-related potentials will be recorded using a bio-signal amplifier with CE & FDA approval (g.HIamp, g.tec company ) from 62 scalp sites.;Amplitude of event-related potentials with early latency (<300 ms). Timepoint: Immediately before and after intervention. Method of measurement: Event-related potentials will be recorded using a bio-signal amplifier with CE & FDA approval (g.HIamp, g.tec company ) from 62 scalp sites. | — |
Secondary
| Measure | Time frame |
|---|---|
| Functional brain connectivity. Timepoint: Before intervention-after intervention. Method of measurement: Weighted Phase Lag Index.;Effective brain connectivity. Timepoint: Before intervention-after intervention. Method of measurement: Granger causality method.;?electric neuronal activities. Timepoint: Before intervention-after intervention. Method of measurement: Source reconstruction methods such as Standardized low-resolution brain electromagnetic tomography (sLORETA).;Craving for Methamphetamin. Timepoint: Before, during & after. Method of measurement: Visual Analogue Scale (VAS).;Craving for Methamphetamine. Timepoint: Before & after. Method of measurement: Desire for Drug Questionnaire.;Depression. Timepoint: After intervention. Method of measurement: Depression Anxiety and Stress Scale (DASS).;Impulsivity. Timepoint: After Intervention. Method of measurement: Barratt Impulsiveness Scale.;Positive & Negative Affect. Timepoint: Before and After Intervention. Method of measurement: Positive and Negative Affect Scale.;Anxiety. Timepoint: After Intervention. Method of measurement: Depression Anxiety and Stress Scale (DASS).;Stress. Timepoint: ????? ????????????. Method of measurement: Depression Anxiety and Stress Scale (DASS). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHassan Khajehpour
Tehran University of Medical Sciences
Outcome results
None listed